Valuation — not yet established
No valuation for Edgewise Therapeutics is on record yet — no priced round, mark, or trade has surfaced in our sources. Total raised ($95.0M) and the funding record below are the closest available signals.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
See the evidence behind this price
- ·Post-money valuations for all 3 rounds
- ·Watchlist + deal alerts for Edgewise Therapeutics
Create free account
No card required
Funding history
3 rounds| Date | Round | Raised | Post-money | $/share |
|---|---|---|---|---|
| Feb 2022 | PIPE | — | ▮ | ▮ |
| Dec 2020 | Later Stage VC (Series C) | $95.0M | ▮ | ▮ |
| Aug 2019 | Early Stage VC | $25.1M | ▮ | ▮ |
How Edgewise Therapeutics's valuation is determined
Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.
For Edgewise Therapeutics, too few pricing signals exist to publish a composite mark; the figures above reflect the most recent observed valuation event. Full methodology →
Frequently asked
- How much has Edgewise Therapeutics raised?
- Edgewise Therapeutics has raised $95.0M in total funding across 3 recorded rounds.
- When did Edgewise Therapeutics last raise?
- Edgewise Therapeutics last raised in Feb 2022 (PIPE).